SOM Biotech is a drug repositioning company using a proprietary ligand-based screening computational tool to identify new therapeutic activities of approved compounds, providing new repositioned candidates that might reach the market faster than traditional therapies. Our approach has been proved successful in different diseases like psoriasis and amyloidosis. The company’s expertise in drug repositioning can be applied to different therapeutic areas for which there is an urgent need of new and safe treatments. Once validation of new therapeutic activity with appropriate in vitro and in vivo models of disease; the company obtains strong patent protection, and pursues licensing and joint-venture agreements for the further development of the repositioned drugs.
SOM’s discovery platform is a proprietary ligand-based virtual screening software that identifies new drug activities based on the comparison of molecular field maps obtained from the 3D structure of chemical ligands. Compares 22 physico-chemical properties of the reference compound with those of a virtual database of more than 9000 compounds including commercialized drugs and products that have reached clinical research. As a result, non-structural analogs are identified, which are products with a similar biological activity but a completely different structure than the reference compound.